Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.0
Scopus CiteScore – 3.7 (CiteScore Tracker 3.3)
Index Copernicus  – 161.11; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

Ahead of print

doi: 10.17219/acem/161766

Publication type: original article

Language: English

License: Creative Commons Attribution 3.0 Unported (CC BY 3.0)

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Cite as:


Doğantekin B, Çakır Güney B, Çelik Ekinci S, et al. Pulmonary-specific quality of life and dyspnea among patients hospitalized for coronavirus disease 2019: Evaluation of patient groups 1, 3 and 6 months after discharge [published online as ahead of print on April 24, 2023]. Adv Clin Exp Med. 2023. doi:10.17219/acem/161766

Pulmonary-specific quality of life and dyspnea among patients hospitalized for coronavirus disease 2019: Evaluation of patient groups 1, 3 and 6 months after discharge

Betül Doğantekin1,A,B,C,D,E, Başak Çakır Güney1,D,E,F, Semiha Çelik Ekinci2,B,C,F, Zeliha Serindağ1,B,C,F, Nurgül Tükel1,B,C,F, Sinem Akkaya Işık2,C,E, Süleyman Kılıç1,B,F, Mustafa Kaplan1,A,F

1 Department of Internal Medicine, University of Health Sciences, Sultan 2. Abdulhamid Han Training Hospital, Istanbul, Turkey

2 Department of Infectious Diseases, University of Health Sciences, Sultan 2. Abdulhamid Han Training Hospital, Istanbul, Turkey

Graphical abstract


Graphical abstracts

Abstract

Background. Short- and long-term lung damage after coronavirus disease 2019 (COVID-19) has been emphasized in many studies, but pulmonary-specific health-related quality of life (HRQOL) has been examined only in a limited capacity.

Objectives. In this study, we aimed to assess pulmonary-specific HRQOL and dyspnea among patients hospitalized for COVID-19 by applying the St George’s Respiratory Questionnaire (SGRQ) to patient groups 1, 3 and 6 months following discharge (groups T1, T3 and T6).

Materials and methods. This cross-sectional study was conducted between April 2020 and December 2020 at a tertiary hospital in Turkey. A total of 345 patients with a definite diagnosis of COVID-19 were included in our research.

Results. Total SGRQ score was significantly lower in the T6 group than in the T1 group (p < 0.001). The SGRQ-Symptom score was similar in the T3 and T6 groups, while the T1 group had significantly higher values (p < 0.001). The SGRQ-Activity score was significantly lower in the T6 group than in the T1 and T3 groups (p = 0.001), while the SGRQ-Impact score was significantly higher in the T6 group compared to the other 2 groups (p < 0.001). When the patients were analyzed statistically in terms of dyspnea, the difference between the baseline and 6-month results was found to be statistically significant (p < 0.001).

Conclusions. Although long-term consequences are still not fully known, the SGRQ scores and dyspnea outcomes of our patients show that pulmonary-specific HRQOL and dyspnea remain at a similar level from discharge until the 6th month after discharge. Studies with extended and longitudinal follow-up are required.

Key words: COVID-19, pulmonary-specific quality of life, St George’s Respiratory Questionnaire (SGRQ), dyspnea

Background

Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), emerged in late 2019 and quickly spread to become a worldwide pandemic.1 As of August 22, 2022, a total of 593,269,262 people were diagnosed with the virus globally, resulting in 6,446,547 deaths.2 Previous studies have shown that COVID-19 affects multiple organs, although the lung is the main organ affected.3, 4 In addition to the effects of the disease on the pulmonary system in the acute phase, the long-term consequences on pulmonary functions and the extent to which they influence health-related quality of life (HRQOL) have been the subject of many studies.5, 6, 7 They showed the presence of chronic symptom burden and poor quality of life in COVID-19 survivors. These studies also show that COVID-19 can affect the HRQOL of patients, as well as healthcare employees and the general population.8, 9, 10, 11 A previous cross-sectional study revealed that COVID-19 patients had poor HRQOL at 1-month follow-up, which was influenced by various risk factors.12 Another study demonstrated a reduction in HRQOL 3 months after recovery from acute COVID-19.13

Many scales have been used to measure the impact of COVID-19 on HRQOL during active disease and follow-up periods.5, 6, 7, 14, 15 However, the majority of scales used assess overall HRQOL, and the number of studies measuring pulmonary-specific HRQOL is limited. The St George’s Respiratory Questionnaire (SGRQ) is a standardized, self-administered test that measures impacts on general health, daily living and perceived well-being in lung-specific chronic diseases such as chronic obstructive pulmonary disease, asthma, bronchiectasis, kyphoscoliosis, sarcoidosis, and cystic fibrosis.16, 17 There are currently very few studies in which SGRQ was applied in the follow-up of COVID-19 patients, and although they confirm that patients’ lung-specific HRQOL improved over time, the number of patients was low and follow-up periods were limited.6, 7, 18 Despite the emphasis on short- and long-term lung damage after COVID-19, little is known about the extent to which these sequelae affect pulmonary-specific HRQOL.

Objectives

This study aimed to determine changes observed over time regarding pulmonary-specific HRQOL and dyspnea symptoms in patients hospitalized for COVID-19 by assessing groups of patients 1, 3 and 6 months after discharge.

Materials and methods

Study design

This cross-sectional single-center study was conducted between April 2020 and December 2020 at the Sultan 2nd Abdulhamid Han Training and Research Hospital (Istanbul, Turkey), a pandemic hospital of the Health Sciences University (Istanbul, Turkey). The Ethics Committee of the Health Sciences University, Hamidiye Clinical Research Institute, approved the study (approval No. 18/7 issued on June 14, 2021). The study conformed to the ethical standards of the Declaration of Helsinki. All study participants provided written informed consent.

Study population

The study included 345 patients diagnosed with COVID-19 using positive SARS-CoV-2 polymerase chain reaction (PCR) test results from nasopharyngeal swab samples or with a conclusive diagnosis of COVID-19 according to computed tomography (CT) and clinical and laboratory findings, as recommended by the relevant guidelines of the World Health Organization (WHO). Other inclusion criteria included age >18 years and serious illness or symptoms caused by or suspected to have been caused by COVID-19 that required hospitalization (intensive care units (ICUs) or wards). Exclusion criteria were refusal to participate, advanced heart failure, deep anemia, advanced chest deformity, neuromuscular diseases that may cause respiratory distress, pregnancy, dialysis, malignancy, long-term immobility, and cognitive problems preventing scale administration.

Data collection

The hospital database identified patients who had passed the 1-month (T1), 3-month (T3) and 6-month (T6) thresholds of discharge (from the day of diagnosis). Participants were randomly selected using patient codes, and each was contacted by trained healthcare personnel via telephone to schedule appointments. A total of 1562 patients were contacted, and 345 randomly selected individuals (115 patients in each group) participated in the study. Data obtained from hospital records during the hospitalization period (inpatient wards or ICUs) included sociodemographic data, comorbidities, smoking status, day of admission after symptom onset, PCR test results, length of hospital stay, symptoms, dialysis requirement, intensive care need, type of respiratory support, and oxygen saturation.

Follow-up consultations with the patients took place in the COVID-19 outpatient clinic, which was established for the follow-up of COVID-19 patients in the Sultan 2nd Abdulhamid Han Training and Research Hospital. All participants were interviewed face-to-face by trained physicians, and provided the SGRQ themselves. Changes in the number of people who developed dyspnea were also evaluated.

The St George’s Respiratory Questionnaire scale and its administration

The SGRQ consists of 76 items divided into 3 sections, including symptoms (assessing respiratory symptoms, frequency and severity), activity (activities causing or limited due to dyspnea) and impacts (aspects associated with functioning and psychological disturbances resulting from respiratory illness). Each section and total score received scores ranging from 0 to 100 points.16, 19 The total score summarizes the overall impact of the illness on health status, with a higher score indicating worse health and 0 indicating best possible health in relation to pulmonary disease. A reduction of 4 units in the SGRQ score after a medical or non-medical intervention is generally accepted in the literature as a valid minimally important difference (MID) of beneficial therapy.17 The patients filled out the questionnaires while seated in a quiet room and after receiving advice on how and why they should fill in the questionnaire and answer all the questions. When the patient finished, the questionnaire was checked to ensure that all questions were answered, and items without a response were shown to the patient who completed it. The 3 SGRQ component scores and the total score were calculated using a Microsoft Excel 2016 spreadsheet (Microsoft Corp., Redmond, USA) called the SGRQ Calculator.

Statistical analyses

All analyses employed IBM SPSS v. 25 (IBM Corp., Armonk, USA) or Number Cruncher Statistical System (NCSS) 2020 Statistical Software (NCSS LLC, Kaysville, USA), with p < 0.05 accepted as statistically significant and 95% confidence intervals (95% CIs) calculated. Quantitative variables are reported as mean ± standard deviation (M ±SD), and qualitative variables as frequency, percentage and median (Q1–Q3 percentile values). The Shapiro–Wilk test and visual inspection of box plots were employed to evaluate data distribution. A comparison of the 2 groups utilized Student’s t-tests or Mann–Whitney U tests, as appropriate. Meanwhile, a one-way analysis of variance (ANOVA) was used to compare 3 groups, followed by a post hoc Bonferroni test, Kruskal–Wallis test or Dunn test, as appropriate. Wilcoxon signed rank test enabled intragroup evaluations, and the relationships between variables were evaluated using Pearson’s or Spearman’s correlation analysis, as appropriate. Further analysis used linear regression models. A comparison of qualitative data utilized a χ2 test with Yates’s correction for continuity or Fisher’s exact test, as appropriate.

Results

The study included 196 males and 149 females, with no significant difference between the groups in terms of sex distribution (p = 0.541). The overall mean age was 53.02 ±16.02 years, and the group means were 60.40 ±13.78 years (T1), 53.89 ±16.10 years (T3) and 44.76 ±16.66 years (T6). There was a significant difference in age between the groups (p < 0.001). While the percentages of patients with dyspnea in the T1 and T3 groups were similar, there was a statistically significant decrease in the percentage of patients with dyspnea in the T6 group (p < 0.001). Table 1 presents total and individual values and the differences between groups for comorbidities, smoking status, day of admission after symptom onset, PCR positivity, length of hospital stay, symptoms, dialysis need, intensive care need, oxygen saturation, and type of ventilation support.

Although the SGRQ-Total score was significantly lower in the T6 group than in the T1 group (p < 0.001), no significant difference was observed when the T3 group was compared to the other 2 groups. Meanwhile, the SGRQ-Symptom score was similar in the T3 and T6 groups, and significantly lower in both groups relative to the T1 group (p < 0.001). The SGRQ-Activity score was significantly lower in the T6 group than in the T1 and T3 groups (p = 0.001), while values were similar in the T1 and T3 groups. Likewise, the T1 and T3 groups had similar SGRQ-Impact scores, and the T6 group had significantly higher values compared to the other 2 groups (p < 0.001) (Table 2 and Figure 1).

A multiple linear regression analysis revealed that the unstandardized β coefficient for the SGRQ-Total score in the T6 group was 1.106 points lower than in the T1 group (p = 0.001), and in the T3 group it was 0.739 points lower than in the T1 group (p = 0.019) after adjusting for age, sex, chronic disease, smoking status, and PCR result. In addition, being female (β = 1.074) and having a chronic disease (β = 1.008) significantly increased the SGRQ-Total score (p < 0.01).

The unstandardized β coefficient for the SGRQ-Symptom score was 0.768 points lower in the T6 group than in the T1 group (p = 0.003), and in the T3 group it was 0.782 points lower than in the T1 group (p = 0.001), after adjusting for age, sex, chronic disease, smoking status, and PCR result. Also, being female (β = 0.504) significantly increased the SGRQ-Symptom score (p < 0.05).

The unstandardized β coefficient for the SGRQ-Activity score was 1432 points lower in the T6 group than in the T1 group (p = 0.004) after adjusting for age, sex, chronic disease, smoking status, and PCR result. Furthermore, being female (β = 1.572) and having a chronic disease (β = 1.528) significantly increased the SGRQ-Activity score (p < 0.01).

The unstandardized β coefficient for the SGRQ-Impact score was 1270 points lower in the T6 group than in the T1 group (p = 0.001), and in the T3, it was 0.951 points lower than in the T1 group (p = 0.008), after adjusting for age, sex, chronic disease, smoking status, and PCR result. Moreover, being female (β = 1.062) and having a chronic disease (β = 1.144) significantly increased the SGRQ-Impact score (p < 0.01) (Table 3).

Discussion

Although the primary goal of treating hospitalized COVID-19-infected patients is limiting mortality, it has become clear that these infections can have significant long-term effects. Thus, healthcare systems have begun to open clinics dedicated to diagnosing and treating symptoms that persist following COVID-19.20 The primary aim of this study was to show how the pulmonary-specific HRQOL of COVID-19 patients changed in the 1st, 3rd and 6th months after discharge. The secondary aim was to assess changes in the number of patients with dyspnea during this period. According to the results, the SGQR-Total, SGQR-Activity and SGQR-Impact domains of the SGRQ score decreased gradually from the 1st month to the 6th month. The SGRQ-Syptom score was similar in the T3 and T6 groups, while the T1 group had significantly higher values. A higher score means worse health and a score of 0 indicates the best possible health status regarding lung disease. The multiple regression analysis also confirmed these significant relationships. In addition, the number of patients with dyspnea decreased significantly after 6 months.

The rate and severity of long-term pulmonary complications after COVID-19 are currently unknown. Nonetheless, current research shows that there can be a variety of persistent respiratory symptoms several months after recovery from SARS-CoV-2 infection.21 The long-term effects of COVID-19 on HRQOL and mental wellbeing have been evaluated in several studies using various scales,4, 5, 6, 9, 15, 21, 22, 23 such as the SGRQ, which is a pulmonary-specific HRQOL scale used for the evaluation of diseases such as chronic obstructive pulmonary disease, asthma, bronchiectasis, kyphoscoliosis, sarcoidosis, and cystic fibrosis.16, 17 However, studies using pulmonary-specific HRQOL rating scales for COVID-19 are scarce. One such study used the SGRQ to assess patients with pneumonia and severe respiratory failure due to COVID-19 on the day they were discharged and on the 15th day after discharge, and found a significant decrease in all 3 domain scores and total scores when comparing results from day 15 to those from the day of discharge.6 Zhou et al. also used the SGRQ in a prospective cohort study in which they divided COVID-19 patients into severe/critical, mild/moderate, asymptomatic, and healthy control groups. The SGRQ evaluation performed 3 months after recovery showed that the impact score, symptom score, activity score, and total score increased as the severity of the disease increased. However, the study did not measure how the score changed over time.24 Likewise, another study showed that the adapted SGRQ (aSGRQ) improved in hospitalized patients 6–8 weeks after discharge compared to baseline, though scores were still worse than in the general population. The same study reported a significant association between the male sex and hospitalization with a reduced quality of life.25

In a study of healthcare workers in Wuhan, China, that presented results from patients 1 year after discharge, the median SGRQ-Total score was higher than that of healthy controls, and the SGRQ-Total score and all 3 subscale scores were significantly higher in the critical/severe disease group than in the mild/moderate disease group.26 The results of the current study support the findings of similar studies using SGRQ. Indeed, the total score, symptom score, activity score, and impact score in the T6 group were significantly better than the T1 group. Furthermore, there were no differences between the T3 and T1 groups for total, activity and impact scores. Also, symptom scores were lower in T3 than in T1 but similar to T6, which was confirmed using the multiple regression analysis. Considering the follow-ups for improvement in the SGRQ score, it is thought that the evaluations to be made at the 6th month will be the most appropriate response time to treatment, though these data should be supported by more comprehensive studies with more homogeneous patient groups and longitudinal assessments.

Dyspnea is a subjective symptom of respiratory distress, usually developing 7–8 days after the onset of COVID-19 symptoms, and is more common in patients with severe illness.6 Even 2–3 months after discharge, approx. 50% of patients who recover from COVID-19 may continue to complain of dyspnea at rest and during exercise or daily activities.6 Dyspnea is associated with reduced functional capacity and a lower HRQOL.27 Several studies reported dyspnea as the most common symptom observed during follow-up after COVID-19.28 In a prospective study, persistent dyspnea was common and reported by 58.4% of patients 1 year after discharge from ICU.28 In another prospective study, dyspnea was reported in 54% of the participants 3 months after discharge, although there was no difference between patients admitted to the ICU and those who were not.14 In our study, dyspnea was the most common initial symptom. However, there was no significant change in the number of patients with dyspnea in the T3 group compared to the T1 group. Although complaints of dyspnea did not return to a normal level for a given population, there were significant decreases in this regard after 6 months. Therefore, longer follow-up studies are required to understand the mechanisms of persistent dyspnea in survivors and to improve patient management after COVID-19.

Limitations of the study

Patients included in the three-time periods were not the same individuals, but different, which was considered a limitation of our study. The most important reason for this was the necessity of face-to-face interviews with the patients since the validity of administering the SGRQ questionnaire via other means has not been confirmed.16 Another limitation was the inevitable consequence of heterogeneity between patient groups. Although many differences between the groups, including age, seem to be a limitation, this disadvantage was minimized by the multiple regression analysis adjusted for parameters such as age, sex, chronic disease, smoking status, and PCR result. In addition, there was no difference between the groups in terms of pulmonary comorbidity.

A control group was not included due to the difficulty in conducting the questionnaire and the nature of the study. Furthermore, a control group was deemed unnecessary based on the evident differences between controls and patients with COVID-19. Although the follow-up period was relatively longer than in previous studies, the reversibility of pulmonary injury in the longer term is a matter of debate, and further follow-up could be necessary to elucidate possible improvements.

The laboratory and radiological findings and treatment characteristics that may affect the outcome were not specified in the groups. Indeed, viral load may be an important marker for the prognosis of COVID-19, but it was not examined in this study.

Advantages of this study over similar studies include a 3-stage follow-up period evaluated, which allowed for the assessment of gradual changes in pulmonary-specific HRQOL. Furthermore, the number of participants was higher than in most of similar studies. Nonetheless, studies with a larger patient count, longer follow-up periods, more homogeneous patient groups, and more detailed data are needed to confirm these results.

Conclusions

In conclusion, this study found that the SGRQ-Total, -Activity and -Impact scores of patients discharged after COVID-19 were lower in the T6 group compared to the T1 and T3 groups. Of note, the T6 and T3 groups demonstrated significantly better results compared to the T1 group in terms of SGRQ-Symptom scores. There was also a significant improvement in pulmonary-specific HRQOL and dyspnea complaints in the T6 group. Studies on the effects of COVID-19 on pulmonary-specific HRQOL are important to allow for a better preparation for future outbreaks caused by new variants of SARS-CoV-2 or other microorganisms. Furthermore, studies with a more homogeneous distribution of patient characteristics that employ long-term follow-up are required to assess and appropriately manage persistent lung injury in COVID-19.

Supplementary materials

The supplementary files are available at https://doi.org/10.5281/zenodo.7742320. The package contains the following files:

Supplementary Table 1. Normal distribution.

Supplementary Table 2. Predicting SGRQ-Total score.

Supplementary Table 3. Predicting SGRQ-Activity score.

Supplementary Table 4. Predicting SGRQ-Symptom score.

Supplementary Table 5. Predicting SGRQ-Impact score.

Supplementary Fig. 1. Distribution of SGRQ-Total scores.

Supplementary Fig. 2. Distribution of SGRQ-Symptom scores.

Supplementary Fig. 3. Distribution of SGRQ-Activity scores.

Supplementary Fig. 4. Distribution of SGRQ-Impact scores.

Supplementary Fig. 5. SGRQ-Total score distribution Q-Q plots.

Supplementary Fig. 6. SGRQ-Symptom score distribution Q-Q plots.

Supplementary Fig. 7. SGRQ-Activity score distribution Q-Q plots.

Supplementary Fig. 8. SGRQ-Impact score distribution Q-Q plots.

Supplementary Fig. 9. SGRQ-Total score detrended normal Q-Q plots.

Supplementary Fig. 10. SGRQ-Symptom score detrended normal Q-Q plots.

Supplementary Fig. 11. SGRQ-Activity score detrended normal Q-Q plots.

Supplementary Fig. 12. SGRQ-Impact score detrended normal Q-Q plots.

Supplementary Fig. 13. Box plot of SGRQ-Total score and sub-factors.

Tables


Table 1. Summary of patient characteristics and COVID-19-related characteristics with regard to evaluation time

Patient characteristics

Time

Test value

p-value

total (n = 345)

T1 (n = 115)

T3 (n = 115)

T6 (n = 115)

Age

F = 29.264

<0.001º

M ±SD

53.02 ±16.02

60.40 ±13.78

53.89 ±16.10

44.76 ±16.66

Median (IQR)

54 (42–66)

60 (47–75)a

57 (43–66)b

45 (27–57)c

Sex

χ2 = 1.229

0.541

Male

196 (56.8%)

64 (55.7%)

62 (53.9%)

70 (60.9%)

Female

149 (43.2%)

51 (44.3%)

53 (46.1%)

45 (39.1%)

Comorbidities

189 (54.8%)

76 (66.1%)a

69 (60.0%)a

44 (38.3%)b

χ2 = 19.869

<0.001

Diabetes mellitus

93 (27.0%)

39 (33.9%)

30 (26.1%)

24 (20.9%)

χ2 = 5.035

0.081

Hypertension

119 (34.5%)

50 (43.5%)a

42 (36.5%)ab

27 (23.5%)b

χ2 = 10.493

0.005

Coronary artery disease

38 (11.0%)

19 (16.5%)a

14 (12.2%)ab

5 (4.3%)b

χ2 = 8.931

0.011

Heart failure (mild–moderate)

17 (4.9%)

8 (7.0%)

7 (6.1%)

2 (1.7%)

χ2 = 3.836

0.147

Asthma/COPD

35 (10.1%)

15 (13.0%)

13 (11.3%)

7 (6.1%)

χ2 = 3.307

0.191

Rheumatic disease

13 (3.8%)

2 (1.7%)

6 (5.2%)

5 (4.3%)

F.χ2 = 2.147

0.450

Chronic renal disease

13 (3.8%)

4 (3.5%)

7 (6.1%)

2 (1.7%)

F.χ2 = 2.857

0.251

Hypothyroidism

14 (4.1%)

5 (4.3%)

6 (5.2%)

3 (2.6%)

F.χ2 = 1.042

0.700

Smoking

48 (13.9%)

7 (6.1%)a

16 (13.9%)ab

25 (21.7%)b

χ2 = 11.761

0.003

Admission day after symptoms onset

K–W = 5.049

0.080

M ±SD

4.58 ±3.37

4.73 ±2.89

4.61 ±3.03

4.39 ±4.08

Median (IQR)

4 (2–7)

4 (3–6)

4 (2–7)

3 (2–6)

Positive PCR

270 (78.3%)

94 (81.7%)ab

96 (83.5%)b

80 (69.6%)a

χ2 = 7.769

0.021

Length of hospital stay

K–W = 1.033

0.596

M ±SD

9.16 ±6.12

9.12 ±5.88

8.56 ±4.99

9.80 ±7.26

Median (IQR)

7 (5–13)

7 (5–12)

7 (5–11)

8 (5–14)

Symptoms

Fever

178 (51.6%)

60 (52.2%)

63 (54.8%)

55 (47.8%)

χ2 = 1.137

0.566

Cough

190 (55.1%)

56 (48.7%)a

58 (50.4%)a

76 (66.1%)b

χ2 = 8.528

0.014

Sore throat

58 (16.8%)

16 (13.9%)

18 (15.7%)

24 (20.9%)

χ2 = 2.155

0.340

Myalgia/arthralgia

110 (31.9%)

35 (30.4%)

41 (35.7%)

34 (29.6%)

χ2 = 1.148

0.563

Fatigue

142 (41.2%)

42 (36.5%)

53 (46.1%)

47 (40.9%)

χ2 = 2.178

0.337

Headache

55 (15.9%)

15 (13.0%)

20 (17.4%)

20 (17.4%)

χ2 = 1.082

0.582

Nausea/vomiting

44 (12.8%)

11 (9.6%)

22 (19.1%)

11 (9.6%)

χ2 = 5.857

0.051

Diarrhea

44 (12.8%)

4 (3.5%)a

17 (14.8%)b

23 (20.0%)b

χ2 = 14.744

0.001

Dyspnea

141 (40.9%)

67 (58.3%)a

51 (44.3%)a

23 (20.0%)b

χ2 = 1.222

<0.001

Stay in intensive care unit

27 (7.8%)

11 (9.6%)

9 (7.8%)

7 (6.1%)

χ2 = 0.964

0.617

Ventilation support

Mechanical ventilation

5 (1.4%)

4 (3.5%)

1 (0.9%)

0 (0.0%)

χ2 = 4.245

0.133

Non-invasive mechanical ventilation

14 (4.1%)

5 (4.3%)

6 (5.2%)

3 (2.6%)

F.χ2 = 1.080

0.700

High-flow

16 (4.6%)

6 (5.2%)

6 (5.2%)

4 (3.5%)

χ2 = 0.524

0.769

Nasal

156 (45.2%)

86 (74.8%)a

42 (36.5%)b

28 (24.3%)b

χ2 = 64.310

<0.001

Mask

84 (24.3%)

40 (34.8%)a

26 (22.6%)ab

18 (15.7%)b

χ2 = 11.708

0.003

Prone position

18 (5.2%)

4 (3.5%)

10 (8.7%)

4 (3.5%)

χ2 = 4.220

0.121

Oxygen saturation

F = 20.795

<0.001º

M ±SD

94.43 ±4.21

92.82 ±4.57

94.29 ±4.55

96.20 ±2.47

Median (IQR)

96 (93–97)

94 (91–96)a

96 (93–97)b

97 (95–98)c

T1 – group assessed after 1 month; T3 – group assessed after 3 months; T6 – group assessed after 6 months; M – mean; SD – standard deviation; IQR – interquartile range; ANOVA – analysis of variance; COPD – chronic obstructive pulmonary disease; PCR – polymerase chain reaction. Data are given as M ±SD, median (1st quartile–3rd quartile) for continuous variables according to normality of distribution and as frequency (percentage) for categorical variables. ºone-way ANOVA test and post hoc Bonferroni test (F); χ2 test; Kruskal–Wallis test and post hoc Dunn test (K–W); Fisher–Freeman–Halton test (Fχ2). Values in bold are statistically significant. The presence of the same superscripted letters in different columns indicates that the values for those time points were similar according to Bonferroni correction. If 2 columns do not have the same superscripted letter, this means that those time points demonstrated a significant difference from each other according to Bonferroni correction.
Table 2. Summary of St George’s Respiratory Questionnaire (SGRQ) scores and dyspnea status with regard to evaluation time

SGRQ total scores

Time

Test value

SGRQ

total (n = 345)

T1 (n = 115)

T3 (n = 115)

T6 (n = 115)

p-value

Total

<0.001

Median (IQR)

26.15 (6.97–46.76)

33.43 (15.09–54.66)a

26.57 (6.13–46.18)ab

12.68 (3.23–42.31)b

K–W:15.548

Symptom

<0.001

Median (IQR)

19.80 (10.88–34.38)

26.07 (15.44–41.03)a

17.34 (10.75–29.87)b

17.16 (6.32–33.09)b

K–W:16.940

Activity

0.001

Median (IQR)

42.34 (0.00–67.67)

53.62 (18.65–72.82)a

47.69 (0.00–72.29)a

19.24 (0.00–60.03)b

K–W:13.830

Impact

<0.001

Median (IQR)

22.26 (3.97–50.12)

30.61 (8.28–52.18)a

23.56 (4.51–62.84)a

9.12 (0.00–31.16)b

K–W:16.714

T1 – group assessed after 1 month; T3 – group assessed after 3 months; T6 – group assessed after 6 months; IQR – interquartile range. Data are given as median (1st quartile–3rd quartile) for continuous variables according to normality of distribution and as frequency (percentage) for categorical variables. Kruskal–Wallis test and post hoc Dunn test (K–W). The presence of the same superscripted letters in different columns indicates that the values for those time points were similar according to Bonferroni correction. If 2 columns do not have the same superscripted letter, this means that those time points demonstrated a significant difference from each other according to Bonferroni correction.
Table 3. Relationship between time and St George’s Respiratory Questionnaire (SGRQ) scores

Variables

SGRQ-Total score

SGRQ-Symptoms score

SGRQ-Activity score

SGRQ-Impact score

unstandardized β

t

p-value

unstandardized β

t

p-value

unstandardized β

t

p-value

unstandardized β

t

p-value

Constant

4.570

7.277

<0.001

4.685

9.730

<0.001

5.155

5.561

<0.001

3.701

5.155

0.009

Time = T3 (+)

−0.739

2.366

0.019

−0.782

−3.267

0.001

−0.653

−1.417

0.157

−0.951

−2.666

0.008

Time = T6 (+)

−1.106

−3.282

0.001

−0.768

−2.970

0.003

−1.432

−2.879

0.004

−1.270

−3.295

<0.001

Age

−0.002

−0.255

0.799

0.002

0.209

0.835

−0.009

−0.624

0.533

−0.003

−0.287

0.774

Sex, female

1.074

4.048

<0.001

0.504

2.477

0.014

1.572

4.012

<0.001

1.062

3.501

0.001

Chronic disease (+)

1.008

3.343

0.001

0.317

1.369

0.172

1.528

3.432

0.001

1.144

3.318

0.001

Smoking (+)

0.277

0.711

0.477

0.541

1.816

0.070

−0.295

−0.515

0.607

0.484

1.089

0.277

Positive PCR (+)

0.008

0.027

0.979

0.084

0.353

0.724

−0.252

−0.551

0.582

0.197

0.557

0.578

Dependent variables

Dependent variable: SGRQ-Total score; R2 = 0.144; F = 8.105; p < 0.001

Dependent variable: SGRQ-Symptoms score; R2 = 0.078; F = 4.051; p = 0.001

Dependent variable: SGRQ-Activity score; R2 = 0.139; F = 7.447; p < 0.001

Dependent variable: SGRQ-Impact score; R2 = 0.133; F = 7.372; p < 0.001

T1 – group assessed after 1 month; T3 – group assessed after 3 months; T6 – group assessed after 6 months; PCR – polymerase chain reaction. reference category – group assessed after 1 month.

Figures


Fig. 1. Relationship between time and St George’s Respiratory Questionnaire (SGRQ) scores

References (28)

  1. Fortarezza F, Pezzuto F, Hofman P, et al. COVID-19 pulmonary pathology: The experience of European pulmonary pathologists throughout the first two waves of the pandemic. Diagnostics (Basel). 2022;12(1):95. doi:10.3390/diagnostics12010095
  2. World Health Organization (WHO). WHO Coronavirus (COVID-19) Dashboard. Geneva, Switzerland: World Health Organization (WHO); 2020–2023. https://covid19.who.int/. Accessed August 22, 2022.
  3. Zhang S, Bai W, Yue J, et al. Eight months follow-up study on pulmonary function, lung radiographic, and related physiological characteristics in COVID-19 survivors. Sci Rep. 2021;11(1):13854. doi:10.1038/s41598-021-93191-y
  4. Meys R, Delbressine JM, Goërtz YMJ, et al. Generic and respiratory-specific quality of life in non-hospitalized patients with COVID-19. J Clin Med. 2020;9(12):3993. doi:10.3390/jcm9123993
  5. van der Sar-van der Brugge S, Talman S, Boonman-de Winter L, et al. Pulmonary function and health-related quality of life after COVID-19 pneumonia. Respir Med. 2021;176:106272. doi:10.1016/j.rmed.2020.106272
  6. Santus P, Tursi F, Croce G, et al. Changes in quality of life and dyspnoea after hospitalization in COVID-19 patients discharged at home. Multidiscip Res Med. 2020;15(1):713. doi:10.4081/mrm.2020.713
  7. Daher A, Balfanz P, Cornelissen C, et al. Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae. Respir Med. 2020;174:106197. doi:10.1016/j.rmed.2020.106197
  8. Qu G, Zhen Q, Wang W, et al. Health-related quality of life of COVID-19 patients after discharge: A multicenter follow-up study. J Clin Nurs. 2021;30(11–12):1742–1750. doi:10.1111/jocn.15733
  9. Sünnetçi Silistre E, Hatipoğlu HU, Yeşilbaş O, Şükrü Gürbüz F, Ozturk E, Yalçinkaya A. Investigating the psychological impact of COVID-19 on healthcare workers in the intensive care unit. J Surg Med. 2022;6(1):29–35. doi:10.28982/josam.1037054
  10. Nguyen HC, Nguyen MH, Do BN, et al. People with suspected COVID-19 symptoms were more likely depressed and had lower health-related quality of life: The potential benefit of health literacy. J Clin Med. 2020;9(4):965. doi:10.3390/jcm9040965
  11. Zhang Y, Ma ZF. Impact of the COVID-19 pandemic on mental health and quality of life among local residents in Liaoning province, China: A cross-sectional study. Int J Environ Res Public Health. 2020;17(7):2381. doi:10.3390/ijerph17072381
  12. Chen KY, Li T, Gong FH, Zhang JS, Li XK. Predictors of health-related quality of life and influencing factors for COVID-19 patients: A follow-up at one month. Front Psychiatry. 2020;11:668. doi:10.3389/fpsyt.2020.00668
  13. van den Borst B, Peters JB, Brink M, et al. Comprehensive health assessment 3 months after recovery from acute coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2021;73(5):e1089–e1098. doi:10.1093/cid/ciaa1750
  14. Lerum TV, Aaløkken TM, Brønstad E, et al. Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19. Eur Respir J. 2021;57(4):2003448. doi:10.1183/13993003.03448-2020
  15. Labarca G, Henríquez-Beltrán M, Lastra J, et al. Analysis of clinical symptoms, radiological changes and pulmonary function data 4 months after COVID-19. Clin Respir J. 2021;15(9):992–1002. doi:10.1111/crj.13403
  16. Jones PW, Forde Y. St George’s respiratory questionnaire manual. St Georges University of London: London, UK; Version 2.3, June 2009. https://meetinstrumentenzorg.nl/ wp-content/uploads/instrumenten/SGRQ-handl-Eng.pdf
  17. Faverzani S, Nocera F, Crisafulli E, et al. Home-based unsupervised pulmonary rehabilitation program improves the respiratory disability in systemic sclerosis patients with dyspnea: An observational prospective study. Monaldi Arch Chest Dis. 2021;92(3). doi:10.4081/monaldi.2021.1984
  18. Patel K, Straudi S, Yee Sien N, Fayed N, Melvin JL, Sivan M. Applying the WHO ICF Framework to the outcome measures used in the evaluation of long-term clinical outcomes in coronavirus outbreaks. Int J Environ Res Public Health. 2020;17(18):6476. doi:10.3390/ijerph17186476
  19. Jones PW, Quirk FH, Baveystock CM. The St George’s Respiratory Questionnaire. Respir Med. 1991;85:25–31. doi:10.1016/S0954-6111(06)80166-6
  20. Blanco JR, Cobos-Ceballos MJ, Navarro F, et al. Pulmonary long-term consequences of COVID-19 infections after hospital discharge. Clin Microbiol Infect. 2021;27(6):892–896. doi:10.1016/j.cmi.2021.02.019
  21. Ahmed OF, Kakamad FH, Hama Amin BJ, et al. Post COVID-19 pulmonary complications: A single center experience. Ann Med Surg. 2021;72:103052. doi:10.1016/j.amsu.2021.103052
  22. Gamberini L, Mazzoli CA, Sintonen H, et al. Quality of life of COVID-19 critically ill survivors after ICU discharge: 90 days follow-up. Qual Life Res. 2021;30(10):2805–2817. doi:10.1007/s11136-021-02865-7
  23. Bardakci MI, Ozturk EN, Ozkarafakili MA, Ozkurt H, Yanc U, Yildiz Sevgi D. Evaluation of long-term radiological findings, pulmonary functions, and health-related quality of life in survivors of severe COVID-19. J Med Virol. 2021;93(9):5574–5581. doi:10.1002/jmv.27101
  24. Zhou M, Xu J, Liao T, et al. Comparison of residual pulmonary abnormalities 3 months after discharge in patients who recovered from COVID-19 of different severity. Front Med. 2021;8:682087. doi:10.3389/fmed.2021.682087
  25. Righi E, Mirandola M, Mazzaferri F, et al. Long-term patient-centered follow-up in a prospective cohort of patients with COVID-19. Infect Dis Ther. 2021;10(3):1579–1590. doi:10.1007/s40121-021-00461-3
  26. Liao T, Meng D, Xiong L, et al. Long-term effects of COVID-19 on health care workers 1-year post-discharge in Wuhan. Infect Dis Ther. 2022;11(1):145–163. doi:10.1007/s40121-021-00553-0
  27. Cortés-Telles A, López-Romero S, Figueroa-Hurtado E, et al. Pulmonary function and functional capacity in COVID-19 survivors with persistent dyspnoea. Respir Physiol Neurobiol. 2021;288:103644. doi:10.1016/j.resp.2021.103644
  28. Gamberini L, Mazzoli CA, Prediletto I, et al. Health-related quality of life profiles, trajectories, persistent symptoms and pulmonary function one year after ICU discharge in invasively ventilated COVID-19 patients: A prospective follow-up study. Respir Med. 2021;189:106665. doi:10.1016/j.rmed.2021.106665